Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate.
Biotech Company Secures $453 Million Award For Covid-19 Oral Pill Candidate
Biotech Company Secures $453 Million Award…
Biotech Company Secures $453 Million Award For Covid-19 Oral Pill Candidate
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate.